Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Winter;18(1):18-21.
doi: 10.1097/jdpa.0000000000000004.

A Unique Dermatologic Adverse Event from Enfortumab Vedotin

Megan Bielawa  1 , Apoorva Trivedi  2
Affiliations

A Unique Dermatologic Adverse Event from Enfortumab Vedotin

Megan Bielawa et al. J Dermatol Physician Assist. 2024 Winter.

Abstract

Enfortumab vedotin (EV) is a novel chemotherapeutic agent used in the treatment of metastatic urothelial cancer. Although rashes are reported as a common adverse event from this therapy, a paucity of literature is available on dermatologic toxicities to EV, especially with respect to bullous dermatoses. This case report will review a unique bullous dermatosis in the setting of EV therapy, including the diagnostic workup and management. Because cutaneous adverse events to chemotherapy and immunotherapy are common and can often result in dose reduction and treatment withdrawal for cancer patients, awareness of these manifestations and understanding how to manage them is crucial to providing quality care to this patient population.

Keywords: bullous dermatitis; cutaneous toxicities; enfortumab vedotin; immunotherapy; urothelial cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cutaneous findings on initial skin examination
Figure 2.
Figure 2.
Hematoxylin and eosin stains of a punch biopsy obtained from the upper medial thigh
Figure 3.
Figure 3.
Cutaneous findings on skin examination at the two-week follow-up appointment
See this image and copyright information in PMC

References

    1. Lacouture ME, Patel AB, Rosenberg JE, O’Donnell PH. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. 2022;27(3):e223–e232. doi: 10.1093/oncolo/oyac001 - DOI - PMC - PubMed
    1. Padcev. Prescribing information. Astellas Pharma U.S. Inc.; 2021. Updated May, 2022. Accessed November 27, 2022. https://astellas.us/docs/PADCEV_label.pdf
    1. Fabbrocini G, Lacouture ME, Tosti A. Dermatologic Reactions to Cancer Therapies. CRC Press; 2019.
    1. Lacouture ME. Dermatologic Principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. Hoboken, NJ: John Wiley & Sons (Wiley/Blackwell); 2014.
    1. U.S. Department of Health and Human Services. Common terminology criteria for cutaneous adverse events (CTCAE) v5.0. U.S. Department of Health and Human Services; 2017. Accessed November 27, 2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs...